Shandong Sinobioway Biomedicine Co., Ltd. (002581)

Overview

Founded in 2000 and based in Shenzhen, China, Shandong Sinobioway Biomedicine Co., Ltd. is a prominent player in the Chinese pharmaceutical industry, focusing on the research, development, production, and sale of pharmaceutical intermediates. The company boasts a comprehensive portfolio of products that cater to a varied spectrum of healthcare needs, ranging from pharmaceutical intermediates to biopharmaceutical research and development services. As a subsidiary of Shenzhen Yilian Technology Co., Ltd., Shandong Sinobioway Biomedicine Co., Ltd. has established itself as a key contributor to the biopharmaceutical landscape in China.

Products and Services

• Pharmaceutical Intermediates:

  The company's production segment focuses on creating key pharmaceutical intermediates such as trimethyl orthoformate, triethyl orthoformate, trimethyl orthoacetate, phosphorous acid, ethyl formate, and trimethyl acetate, along with their by-products. These intermediates are essential for the synthesis of various pharmaceutical compounds, showcasing the company's pivotal role in the sector's supply chain.

• Biopharmaceutical Products:
  • Anfulan: A human interferon a2b injection that represents the company's innovation in therapeutic treatments catering to specific medical conditions.
  • Jiefu: A human interferon a2b spray designed for ease of use and effectiveness in treating targeted ailments.
  • Enjingfu: A mouse nerve growth factor for injection, indicating the company's commitment to neurological health and recovery.
  • Bellaph: A combined hepatitis A and B vaccine, showcasing the company's dedication to preventing widespread infectious diseases through vaccination.
• Biopharmaceutical Research and Development Services:

  These services encompass a wide range of activities critical to the biopharmaceutical industry, including cell line development, cell bank building, cell culture process development, protein purification process development, preparation prescription and process development, analysis and detection method development, and quality research. These capabilities demonstrate the company's comprehensive engagement with the end-to-end process of biopharmaceutical product development.

• Biopharmaceutical Production Services:

  Shandong Sinobioway Biomedicine Co., Ltd. extends its expertise to biopharmaceutical production services covering preclinical, clinical phase I/II/III, and commercial manufacturing stages. This suggests a robust infrastructural capacity for supporting drug development life cycles from early discovery through to market launch.

• Regulatory Service Support and Drug Registration Affairs:

  The company also offers pivotal services in regulatory support and drug registration, facilitating the navigation through complex regulatory landscapes and ensuring compliance and approval for new drugs. This reflects the company's role as a full-service provider in the biopharmaceutical field.